KR20180041120A - Cprispr/cas9-기반 치료 - Google Patents
Cprispr/cas9-기반 치료 Download PDFInfo
- Publication number
- KR20180041120A KR20180041120A KR1020187002971A KR20187002971A KR20180041120A KR 20180041120 A KR20180041120 A KR 20180041120A KR 1020187002971 A KR1020187002971 A KR 1020187002971A KR 20187002971 A KR20187002971 A KR 20187002971A KR 20180041120 A KR20180041120 A KR 20180041120A
- Authority
- KR
- South Korea
- Prior art keywords
- dna
- homo sapiens
- corneal dystrophy
- dystrophy
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091033409 CRISPR Proteins 0.000 title claims abstract description 32
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 108020004414 DNA Proteins 0.000 claims abstract description 407
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims abstract description 56
- 206010011005 corneal dystrophy Diseases 0.000 claims abstract description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 41
- 230000003228 microsomal effect Effects 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 230000008439 repair process Effects 0.000 claims abstract description 17
- 230000005782 double-strand break Effects 0.000 claims abstract description 15
- 230000008685 targeting Effects 0.000 claims abstract description 13
- 108020005004 Guide RNA Proteins 0.000 claims description 50
- 101710163270 Nuclease Proteins 0.000 claims description 40
- 210000000278 spinal cord Anatomy 0.000 claims description 23
- 206010050389 Cerebral ataxia Diseases 0.000 claims description 19
- 208000018672 Dilatation Diseases 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 206010064571 Gene mutation Diseases 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 210000004087 cornea Anatomy 0.000 claims description 11
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 230000006780 non-homologous end joining Effects 0.000 claims description 9
- 208000033051 Fuchs endothelial corneal dystrophy Diseases 0.000 claims description 8
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 208000036626 Mental retardation Diseases 0.000 claims description 7
- 238000007918 intramuscular administration Methods 0.000 claims description 7
- 206010023365 keratopathy Diseases 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 102000053602 DNA Human genes 0.000 claims description 6
- 108091092878 Microsatellite Proteins 0.000 claims description 6
- 210000000744 eyelid Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 5
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 230000008694 endothelial dysfunction Effects 0.000 claims description 5
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 201000004173 Epithelial basement membrane dystrophy Diseases 0.000 claims description 4
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 4
- 201000004216 Posterior amorphous corneal dystrophy Diseases 0.000 claims description 4
- 201000004223 Reis-Bucklers corneal dystrophy Diseases 0.000 claims description 4
- 230000010339 dilation Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 102100024378 AF4/FMR2 family member 2 Human genes 0.000 claims description 3
- 201000004182 Congenital stromal corneal dystrophy Diseases 0.000 claims description 3
- 206010058314 Dysplasia Diseases 0.000 claims description 3
- 206010015995 Eyelid ptosis Diseases 0.000 claims description 3
- 206010056438 Growth hormone deficiency Diseases 0.000 claims description 3
- 206010072361 Hand-foot-genital syndrome Diseases 0.000 claims description 3
- 101000833172 Homo sapiens AF4/FMR2 family member 2 Proteins 0.000 claims description 3
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 claims description 3
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 claims description 3
- 201000004225 Thiel-Behnke corneal dystrophy Diseases 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 208000001901 epithelial recurrent erosion dystrophy Diseases 0.000 claims description 3
- 230000008826 genomic mutation Effects 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 201000003004 ptosis Diseases 0.000 claims description 3
- 210000003786 sclera Anatomy 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000021907 Central cloudy dystrophy of François Diseases 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 208000005417 Fleck corneal dystrophy Diseases 0.000 claims description 2
- 201000004176 Gelatinous drop-like corneal dystrophy Diseases 0.000 claims description 2
- 206010021750 Infantile Spasms Diseases 0.000 claims description 2
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims description 2
- 208000006335 Lisch epithelial corneal dystrophy Diseases 0.000 claims description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
- 201000004224 Schnyder corneal dystrophy Diseases 0.000 claims description 2
- 208000021332 Syndactyly type 2 Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 201000006791 West syndrome Diseases 0.000 claims description 2
- 201000004175 X-linked endothelial corneal dystrophy Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 210000003109 clavicle Anatomy 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 201000003775 lattice corneal dystrophy Diseases 0.000 claims description 2
- 201000005139 macular corneal dystrophy Diseases 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 208000012584 pre-descemet corneal dystrophy Diseases 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 208000009996 subepithelial mucinous corneal dystrophy Diseases 0.000 claims description 2
- 201000002957 synpolydactyly Diseases 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 201000003415 fragile X-associated tremor/ataxia syndrome Diseases 0.000 claims 3
- 102100032187 Androgen receptor Human genes 0.000 claims 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 claims 2
- 206010066131 Congenital central hypoventilation syndrome Diseases 0.000 claims 2
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 206010005155 Blepharophimosis Diseases 0.000 claims 1
- 201000000304 Cleidocranial dysplasia Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000016031 Haddad syndrome Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 claims 1
- 201000003692 Partington syndrome Diseases 0.000 claims 1
- 208000000474 Poliomyelitis Diseases 0.000 claims 1
- 201000003629 Spinocerebellar ataxia type 8 Diseases 0.000 claims 1
- 206010042778 Syndactyly Diseases 0.000 claims 1
- 208000029305 central congenital hypothyroidism Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000021921 corneal disease Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 208000009624 holoprosencephaly Diseases 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 208000003580 polydactyly Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 abstract 2
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 description 357
- 230000035772 mutation Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 108010048992 Transcription Factor 4 Proteins 0.000 description 6
- 102100023489 Transcription factor 4 Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 5
- 101150017815 TCF4 gene Proteins 0.000 description 5
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 201000004219 Meesmann corneal dystrophy Diseases 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 208000035474 group of disease Diseases 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 201000004207 posterior polymorphous corneal dystrophy Diseases 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000007018 DNA scission Effects 0.000 description 2
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 2
- 206010016202 Familial Amyloidosis Diseases 0.000 description 2
- 241000720913 Fuchsia Species 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- 208000002615 Juvenile Epithelial of Meesmann Corneal Dystrophy Diseases 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 241000208140 Acer Species 0.000 description 1
- 101100480514 Caenorhabditis elegans tag-53 gene Proteins 0.000 description 1
- 208000034717 Congenital hereditary endothelial dystrophy type II Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 201000007888 Finnish type amyloidosis Diseases 0.000 description 1
- 208000031518 Genetic corneal dystrophy Diseases 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000854936 Homo sapiens Visual system homeobox 1 Proteins 0.000 description 1
- 102100023967 Keratin, type I cytoskeletal 12 Human genes 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102100020673 Visual system homeobox 1 Human genes 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000000721 basilar membrane Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 201000004889 corneal granular dystrophy Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000014706 granular corneal dystrophy Diseases 0.000 description 1
- 208000026760 granular corneal dystrophy type I Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000028485 lattice corneal dystrophy type I Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 201000008526 posterior polymorphous corneal dystrophy 1 Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562188013P | 2015-07-02 | 2015-07-02 | |
| US62/188,013 | 2015-07-02 | ||
| PCT/US2016/040962 WO2017004616A1 (en) | 2015-07-02 | 2016-07-05 | Crispr/cas9-based treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180041120A true KR20180041120A (ko) | 2018-04-23 |
Family
ID=57609222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187002971A Withdrawn KR20180041120A (ko) | 2015-07-02 | 2016-07-05 | Cprispr/cas9-기반 치료 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200010854A1 (https=) |
| EP (1) | EP3317409A4 (https=) |
| JP (1) | JP2018520149A (https=) |
| KR (1) | KR20180041120A (https=) |
| CN (1) | CN108350446A (https=) |
| AU (1) | AU2016287836A1 (https=) |
| BR (1) | BR112017028201A2 (https=) |
| CA (1) | CA2989331A1 (https=) |
| CL (1) | CL2017003411A1 (https=) |
| EA (1) | EA201890203A1 (https=) |
| IL (1) | IL256279A (https=) |
| MX (1) | MX2017016921A (https=) |
| WO (1) | WO2017004616A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200044235A (ko) | 2018-10-18 | 2020-04-29 | 대한민국(산림청 국립산림과학원장) | CRISPR-Cas9 시스템을 이용한 유색고약버섯의 리그닌 분해효소의 유전자 편집방법 및 이의 용도 |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| ES2788426T3 (es) | 2014-06-16 | 2020-10-21 | Univ Johns Hopkins | Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1 |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| EP4036228A1 (en) | 2015-11-13 | 2022-08-03 | Avellino Lab USA, Inc. | Methods for the treatment of corneal dystrophies |
| KR20180134412A (ko) * | 2016-04-22 | 2018-12-18 | 인텔리아 테라퓨틱스, 인크. | 전사 인자 4에서 트라이뉴클레오타이드 반복부와 연관된 질환의 치료를 위한 조성물 및 방법 |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2020046861A1 (en) * | 2018-08-27 | 2020-03-05 | Avellino Lab Usa, Inc. | Crispr/cas9 systems, and methods of use thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| WO2018165541A1 (en) | 2017-03-10 | 2018-09-13 | The Board Of Regents Of The University Of Texas System | Treatment of fuchs' endothelial corneal dystrophy |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| WO2018225807A1 (ja) * | 2017-06-07 | 2018-12-13 | 国立大学法人東京大学 | 顆粒状角膜変性症に対する遺伝子治療薬 |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| DE102017131324A1 (de) | 2017-12-27 | 2019-06-27 | Beckhoff Automation Gmbh | Statormodul und Planarantriebssystem |
| CN108949823B (zh) * | 2017-12-29 | 2020-02-14 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 靶向敲除ATXN3基因中扩展突变型polyQ序列的方法 |
| EP3790980A4 (en) * | 2018-05-06 | 2022-03-23 | Emendobio Inc. | DIFFERENTIAL KNOCKOUT OF AN ALLEL OF A HETEROZYGOUS ELAN GENE |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| KR102929494B1 (ko) * | 2018-10-29 | 2026-02-20 | 차이나 어그리컬처럴 유니버시티 | 신규 CRISPR/Cas12f 효소 및 시스템 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021076883A2 (en) * | 2019-10-16 | 2021-04-22 | Brown University | Muscle regeneration and growth |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| CN111849991B (zh) * | 2020-08-05 | 2022-04-08 | 武汉纽福斯生物科技有限公司 | 一种寡核苷酸及其应用 |
| EP4430185A1 (en) * | 2021-11-09 | 2024-09-18 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of fuchs endothelial corneal dystrophy |
| WO2023092132A1 (en) * | 2021-11-22 | 2023-05-25 | Mammoth Biosciences, Inc. | Effector proteins and uses thereof |
| IL320664A (en) * | 2022-11-02 | 2025-07-01 | Emendobio Inc | Compositions and methods for transcription factor 4 (tcf4) repeat expansion excision |
| CN116286823A (zh) * | 2023-04-04 | 2023-06-23 | 尧唐(上海)生物科技有限公司 | 靶向TGFBI基因的sgRNA、载体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014093655A2 (en) * | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| WO2015048577A2 (en) * | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| JP6712948B2 (ja) * | 2013-12-12 | 2020-06-24 | ザ・ブロード・インスティテュート・インコーポレイテッド | 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法 |
| JP7103750B2 (ja) * | 2013-12-12 | 2022-07-20 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用 |
| KR20180134412A (ko) * | 2016-04-22 | 2018-12-18 | 인텔리아 테라퓨틱스, 인크. | 전사 인자 4에서 트라이뉴클레오타이드 반복부와 연관된 질환의 치료를 위한 조성물 및 방법 |
-
2016
- 2016-07-05 CN CN201680050474.4A patent/CN108350446A/zh active Pending
- 2016-07-05 BR BR112017028201A patent/BR112017028201A2/pt not_active Application Discontinuation
- 2016-07-05 KR KR1020187002971A patent/KR20180041120A/ko not_active Withdrawn
- 2016-07-05 JP JP2017567629A patent/JP2018520149A/ja active Pending
- 2016-07-05 EP EP16818953.8A patent/EP3317409A4/en not_active Withdrawn
- 2016-07-05 US US15/741,444 patent/US20200010854A1/en not_active Abandoned
- 2016-07-05 AU AU2016287836A patent/AU2016287836A1/en not_active Abandoned
- 2016-07-05 EA EA201890203A patent/EA201890203A1/ru unknown
- 2016-07-05 MX MX2017016921A patent/MX2017016921A/es unknown
- 2016-07-05 CA CA2989331A patent/CA2989331A1/en not_active Abandoned
- 2016-07-05 WO PCT/US2016/040962 patent/WO2017004616A1/en not_active Ceased
-
2017
- 2017-12-12 IL IL256279A patent/IL256279A/en unknown
- 2017-12-27 CL CL2017003411A patent/CL2017003411A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200044235A (ko) | 2018-10-18 | 2020-04-29 | 대한민국(산림청 국립산림과학원장) | CRISPR-Cas9 시스템을 이용한 유색고약버섯의 리그닌 분해효소의 유전자 편집방법 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2989331A1 (en) | 2017-01-05 |
| US20200010854A1 (en) | 2020-01-09 |
| EA201890203A1 (ru) | 2018-07-31 |
| IL256279A (en) | 2018-02-28 |
| BR112017028201A2 (pt) | 2018-08-28 |
| CL2017003411A1 (es) | 2018-08-17 |
| WO2017004616A1 (en) | 2017-01-05 |
| EP3317409A1 (en) | 2018-05-09 |
| JP2018520149A (ja) | 2018-07-26 |
| MX2017016921A (es) | 2018-04-10 |
| AU2016287836A1 (en) | 2018-02-15 |
| EP3317409A4 (en) | 2019-02-20 |
| CN108350446A (zh) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180041120A (ko) | Cprispr/cas9-기반 치료 | |
| Tsai et al. | Clustered regularly interspaced short palindromic repeats-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa | |
| JP2018520149A5 (https=) | ||
| JP2021503945A5 (https=) | ||
| Banfi et al. | Identification and characterization of AFG3L2, a novel paraplegin-related gene | |
| JP2019500348A (ja) | 眼疾患の処置のための組成物および方法 | |
| AU2019255708B2 (en) | Trans-splicing molecules | |
| CN114040974A (zh) | 用于高效rna反式剪接的三螺旋终止子 | |
| JP2004532844A (ja) | イオントホレシスのステップを含む方法により送達されるキメラオリゴヌクレオチドでの遺伝子療法 | |
| Nelwan | Treat oculocutaneous albinism with gene therapy | |
| Jang et al. | Recent preclinical and clinical advances in gene therapy for hereditary hearing loss | |
| JP7161730B2 (ja) | 顆粒状角膜変性症に対する遺伝子治療薬 | |
| CN114369600B (zh) | 用于修复Klhl18lowf突变基因的CRISPR/Cas9基因编辑系统及应用 | |
| WO2023163131A1 (ja) | フレームシフト変異に起因する疾患のための医薬 | |
| JP2020528735A (ja) | 反復伸長変異のためのゲノム編集システム | |
| Borrás et al. | Generation of a Matrix Gla (Mgp) floxed mouse, followed by conditional knockout, uncovers a new Mgp function in the eye | |
| US20250340870A1 (en) | Systems, methods, and compositions for altering the expression of endogenous circular rnas | |
| CN114752623B (zh) | 视网膜色素变性疾病动物模型的构建方法和应用 | |
| JP2025504661A5 (https=) | ||
| US20250090690A1 (en) | Methods and systems for correcting mutations in prph2 | |
| WO2020197330A1 (ko) | 혈액응고인자 viii 유전자 역위 보정에 의한 혈우병 치료용 조성물 | |
| KR20190037167A (ko) | 혈액응고인자 viii 유전자 역위 보정능의 유전자 가위 시스템으로 구성된 혈우병 치료용 조성물 | |
| Stefanidakis et al. | Development of a subretinally delivered CEP290-specific CRISPR medicine for the treatment of Leber congenital amaurosis 10 (LCA10) | |
| WO2019005926A1 (en) | VEGFR2 AAV-CRISPR / CAS9 GENOME EDITION FOR THE TREATMENT OF OCULAR DISEASES | |
| Fusumae et al. | 160 Replacing COL7A1-deficient epidermis over the entire body by autografting cultured revertant keratinocytes in severe recessive dystrophic epidermolysis bullosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180130 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |